| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/15/2004 | US20040072852 Anticholesterol agents; cardiovascular disorders |
| 04/15/2004 | US20040072850 Caspase inhibitors and uses thereof |
| 04/15/2004 | US20040072847 Eating disorders; psychological disorders; antidiabetic agents; cardiovascular disorders |
| 04/15/2004 | US20040072846 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 04/15/2004 | US20040072841 Topical administration of oxazolidinones for transdermal delivery |
| 04/15/2004 | US20040072840 Analgesics, antiinflammatory agents, antiallergens, autoimmune disease, cardiovascular disorders |
| 04/15/2004 | US20040072833 Antidepressants; anxiolytic agents; eating disorders; antiulcer agents; drug abuse; Alzheimer's disease |
| 04/15/2004 | US20040072832 Anticancer agents; antiinflammatory agents |
| 04/15/2004 | US20040072831 Reverse-turn mimetics and method relating thereto |
| 04/15/2004 | US20040072830 Squalene synthetase inhibitors; antilipemic agents; antiischemic agents; cardiovascular disorders; anticholesterol agents |
| 04/15/2004 | US20040072828 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 04/15/2004 | US20040072823 Central nervous system disorders; analgesics; antiinflammatory agents |
| 04/15/2004 | US20040072821 N-substituted glycine derivatives |
| 04/15/2004 | US20040072819 Benzoxazepine compounds, their production and use |
| 04/15/2004 | US20040072816 Dysmenorrhea; congestive heart failure; liver disorders; vision defects |
| 04/15/2004 | US20040072805 Use of tumor necrosis factor inhibitors to treat cardiovascular disease |
| 04/15/2004 | US20040072797 In liquid siolvent; parenterally administering; aldosterone receptors blockers; congestive heart failure, hypotensive agents, liver disorders |
| 04/15/2004 | US20040072762 Diazocine derivatives and their use as tryptase inhibitors |
| 04/15/2004 | US20040072758 Contulakin-G, analogs thereof and uses therefor |
| 04/15/2004 | US20040072751 A kits for use in drug screening antagonists, agonists; a recombinant vector polynucleotide, cell culturing, an antibody used for diagnostic, for adjusting the expression of the G protein-coupled receptor protein |
| 04/15/2004 | US20040072726 Decoy is an NF- kappa B decoy, an ets decoy, or a chimera decoy of NF- kappa B and ets. The disease is cerebral aneurysm, cancer, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic etc. |
| 04/15/2004 | US20040072258 Disruption of a Ras-protein complex by a Ras antagonist, e.g.,farensylthiosalicylic acid, analyzed; identifying drug candidates inhibiting aberrant Ras activity; binding andinactivating mRNA of anchor protein by a oligonucleotides |
| 04/15/2004 | US20040072238 Integrin binding polipeptide for diagnosis, prevention and treatment of renal failure, thrombosis, osteoporosis, cancers and diabetes |
| 04/15/2004 | US20040072174 Calpain protease 12 |
| 04/15/2004 | US20040072172 Comprises enzymatic polypeptide associated with calcium dependent movement of phospholipids through plasmid membranes for diagnosis and treatment of thrombosis, angina pectoris and stroke; gene therapy |
| 04/15/2004 | US20040072170 Using creatine kinase messenger RNA expression profiles to diagnose congestive heart failure |
| 04/15/2004 | US20040071792 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity |
| 04/15/2004 | US20040071776 Diameter of pores of support netweork greater than those of filling; vascular occlusions (embolizations), cellular reconstruction, treatment of gastroesophageal reflux, incontinence, and wrinkle resistance |
| 04/15/2004 | US20040071766 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 04/15/2004 | US20040071731 Chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| 04/15/2004 | US20040071711 Imaging, diagnosis and treatment of disease |
| 04/15/2004 | US20040071691 Including compatible solute; enhancing effectiveness of protein containing active material; reducing cytotoxic activity |
| 04/15/2004 | US20040071686 Treatment of alpha-galactosidase A deficiency |
| 04/15/2004 | US20040071676 Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell |
| 04/15/2004 | US20040071669 Transplants for myocardial scars |
| 04/15/2004 | US20040071655 Binding agent |
| 04/15/2004 | DE10296335T5 Pharmazeutische Formulierungen Pharmaceutical formulations |
| 04/15/2004 | DE10246374A1 New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia |
| 04/15/2004 | CA2500904A1 Composition containing eosinophil cationic protein |
| 04/15/2004 | CA2500895A1 Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 04/15/2004 | CA2500530A1 Therapeutic uses of .beta.-casein a2 and dietary supplement containing .beta.-casein a2 |
| 04/14/2004 | EP1408117A1 Glycoprotein and process for producing the same |
| 04/14/2004 | EP1408040A1 Tricyclic fused heterocyclic compounds as CRFantagonists |
| 04/14/2004 | EP1408038A2 Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
| 04/14/2004 | EP1408030A1 Novel aliphatic compound, method of synthesis, and method of utilization |
| 04/14/2004 | EP1407786A1 Therapeutic inhibitor of vascular smooth muscle cells |
| 04/14/2004 | EP1407782A1 Preventives/remedies for organ functional disorders and organ dysfunction |
| 04/14/2004 | EP1407775A1 Medical preparation for parenteral injection |
| 04/14/2004 | EP1407773A1 A process for the preparation of s (-) amlodipine salts |
| 04/14/2004 | EP1407768A2 The potassium channel opener retigabine for the treatment of diseases |
| 04/14/2004 | EP1407767A1 Pparg agonistic medicinal compositions |
| 04/14/2004 | EP1407275A2 Use of transcription factor nak-1 or genes regulated by transcription factor nak-1 for the diagnosis and/or therapy of inflammatory and malignant diseases |
| 04/14/2004 | EP1407030A2 Methods for large scale production of recombinant dna-derived tpa or k2s molecules |
| 04/14/2004 | EP1407013A1 Mutations in ion channels |
| 04/14/2004 | EP1406930A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 04/14/2004 | EP1406929A2 Glycoprotein vi fusion proteins |
| 04/14/2004 | EP1406922A2 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 04/14/2004 | EP1406908A1 Morpholine-bridged pyrazolopyridine derivatives |
| 04/14/2004 | EP1406900A1 Novel compounds, their preparation and use |
| 04/14/2004 | EP1406899A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 04/14/2004 | EP1406898A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 04/14/2004 | EP1406897A2 Compounds |
| 04/14/2004 | EP1406894A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 04/14/2004 | EP1406892A1 Phenyl pyrazole derivatives as soluble epoxide hydrolase inhibitors |
| 04/14/2004 | EP1406891A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 04/14/2004 | EP1406878A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 04/14/2004 | EP1406877A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 04/14/2004 | EP1406876A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 04/14/2004 | EP1406875A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/14/2004 | EP1406873A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 04/14/2004 | EP1406872A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406867A2 Thiolalkyl benzoic acid derivatives |
| 04/14/2004 | EP1406866A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/14/2004 | EP1406865A2 Succinic acid derivatives |
| 04/14/2004 | EP1406859A1 Substituted 4-aminocyclohexanol derivatives |
| 04/14/2004 | EP1406858A1 Substituted 4-aminocyclohexanols |
| 04/14/2004 | EP1406698A2 Lipoxin analogs as novel inhibitors of angiogenesis |
| 04/14/2004 | EP1406696A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 04/14/2004 | EP1406667A2 METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS |
| 04/14/2004 | EP1406666A2 Adenoviral vectors with cell type specificity for mesenchymal cells |
| 04/14/2004 | EP1406664A2 Targeting chemical compounds to cells |
| 04/14/2004 | EP1406660A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 04/14/2004 | EP1406656A2 METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES |
| 04/14/2004 | EP1406650A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 04/14/2004 | EP1406648A1 The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 04/14/2004 | EP1406644A2 Modified proteins, designer toxins, and methods of making thereof |
| 04/14/2004 | EP1406641A2 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 04/14/2004 | EP1406634A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 04/14/2004 | EP1406633A1 Enhanced drug delivery in transdermal systems |
| 04/14/2004 | EP1406626A2 Sulphonyl aryl hydroxamates and their use as mmp inhibitors |
| 04/14/2004 | EP1406622A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406617A1 Diaminediols for the treatment of alzheimer's disease |
| 04/14/2004 | EP1406616A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 04/14/2004 | EP1406615A1 Kinase inhibitors and the use thereof |
| 04/14/2004 | EP1406614A2 Carvedilol polymorph |
| 04/14/2004 | EP1406613A1 Organic nitrate-based compounds for the treatment of vasculopathies |
| 04/14/2004 | EP1406611A2 Method for treating fibrotic diseases or other indications |
| 04/14/2004 | EP1406609A2 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 04/14/2004 | EP1406608A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| 04/14/2004 | EP1406603A2 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |